Diagnostics slide at BioChem Pharma:
This article was originally published in Clinica
The diagnostics division of Canadian pharmaceutical developer BioChem Pharma suffered a setback in 1996. Diagnostics sales declined 10% to Can$141.3 million ($103 million). BioChem attributed this fall to strong competition in the haematology sector of the business. BioChem's total sales declined 3% to Can$156.9 million and the company's bottom line improved, showing a net profit of Can$33.4 million compared with a net loss of Can$5 million in 1995.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.